Targeting IDH mutations for the treatment of AML

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, explains the mechanisms of isocitrate dehydrogenase (IDH) mutations and their effect on myeloid differentiation, ultima... Author: VJOncology Added: 05/25/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts